Saskia Hüsken

Saskia Hüsken

Auto-generated profile, based on publicly available information

Saskia Hüsken

Department of Otorhinolaryngology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University, Düsseldorf, Germany

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2025 in Environment International
Verified
Journal Article
Open access
KKKatharina Koch
Katharina Koch
KSKevin Schlüppmann
Kevin Schlüppmann
SHSaskia Hüsken
Saskia Hüsken
LSLouisa Merit Stark
Louisa Merit Stark
NFNils Förster
Nils Förster
EFEllen Fritsche
Ellen Fritsche
Despite growing awareness of endocrine disrupting chemicals (EDCs), knowledge gaps remain regarding their effects on human brain development. EDC risk assessment focuses primarily on EATS modalities (estrogens, androgens, thyroid hormones, and steroidogenesis), overlooking the broader range of hormone receptors expressed in the developing brain. This limits the evaluation of chemicals for their potential to cause endocrine disruption-mediated developmental neurotoxicity (ED-DNT). The Neurosphere Assay, an in vitro test method for developmental neurotoxicity (DNT) evaluation, is an integral component of the DNT in vitro testing battery, which has been used to screen a broad domain of environmental chemicals. Here, we define the endocrine-related applicability domain of the Neurosphere Assay by assessing the impact and specificity of 14 hormone receptors on seven key neurodevelopmental processes (KNDPs), neural progenitor cell (NPC) proliferation, migration of radial glia, neurons, and oligodendrocytes, neurite outgrowth, and differentiation of neurons and oligodendrocytes. Comparative analyses in human and rat NPCs of both sexes revealed species- and sex-specific responses. Mechanistic insights were obtained through RNA sequencing and agonist/antagonist co-exposures. Most receptor agonists modulated KNDPs at concentrations in the range of physiologically relevant hormone concentrations. Phenotypic effects induced by glucocorticoid receptor (GR), liver X receptor (LXR), peroxisome proliferator-activated receptor beta/delta (PPARβδ), retinoic acid receptor (RAR) and retinoid X receptor (RXR) activation were counteracted by receptor antagonists, confirming specificity. Transcriptomics highlighted receptor crosstalk and the involvement of conserved developmental pathways (e.g. Notch and Wnt). Species comparisons identified limited concordance in hormone receptor-regulated KNDPs between human and rat NPCs. This study presents novel findings on cellular and molecular hormone actions in human fetal NPCs, highlights major species differences, and illustrates the Neurosphere Assay's relevance for detecting endocrine MoAs, supporting its application in human-based ED-DNT risk assessment.

27 June 2025 in PLOS Genetics
Verified
Journal Article
Open access
SHSaskia Hüsken
Saskia Hüsken
ARAnnika Röder
Annika Röder
JPJohannes Ptok
Johannes Ptok
AMAnne E. Meyer
Anne E. Meyer
MGMats Georg
Mats Georg
CWConstanze Wiek
Constanze Wiek
A hallmark of the highly conserved CYP4B1 enzyme in mammals is the capability to bioactivate both xenobiotic and endobiotic substrates. However, due to a single amino acid change (p.P427S) within the evolutionary conserved meander region no catalytic activity of the native human CYP4B1 has been identified so far. To identify at which point in human evolution the loss of CYP4B1 activity had occurred, we evaluated the activities of CYP4B1 orthologs from 14 primate genera against 4-ipomeanol and perilla ketone in human liver cells. The activity of recombinant CYP4B1 proteins isolated from E. coli was also tested against 4-ipomeanol and lauric acid. Surprisingly, CYP4B1 already became catalytically inactive at the split between apes and monkeys; all tested CYP4B1 orthologs from monkeys were able to bioactivate both protoxins and to hydroxylate lauric acid. Amino acid analysis of the CYP4B1 orthologs revealed four additional evolutionary changes, each affecting the function of ape and human enzymes: p.V71G specific for Denisovans, p.R106C, p.R244H, and an exon deletion found only in the gorilla CYP4B1. Systematic functional analyses proved the negative impact of the genetic changes on CYP4B1 activity and showed that reversion of the mutations restored enzyme activity. The occurrence of five independent inactivating genetic changes in the same gene of closely related species is a clear indication of the importance of inactivating CYP4B1 in apes and humans. Elucidating the evolutionary trigger(s) for CYP4B1 inactivation in our ancestors will ultimately improve our understanding of primate evolution.